The U.S. biomarker-based immunoassays market size was estimated at USD 2.17 billion in 2024 and is projected to reach USD 3.68 billion by 2033, growing at a CAGR of 5.9% from 2025 to 2033. The market growth is fueled by the rising U.S. burden of chronic diseases such as cancer, cardiovascular disorders, and neurological conditions, which require precise and early diagnostic tools. A major driver shaping the scope of this market is the shift toward personalized medicine. Pharmaceutical and biotechnology companies increasingly depend on biomarker-based immunoassays to support companion diagnostics and patient stratification in clinical trials. This integration ensures that targeted therapies reach the right patient groups, improving therapeutic outcomes while reducing healthcare costs. The regulatory environment in the U.S. also plays a crucial role in shaping this scope.
Alongside therapeutic uses, the market is expanding due to technological progress and digital integration. Automated immunoassay platforms combined with artificial intelligence for data analysis are supporting high-throughput and very sensitive biomarker testing. This growth is not limited to central labs but also reaches decentralized healthcare models, like point-of-care and at-home testing options. The use of saliva-based biomarker immunoassays, which are less invasive and simpler to collect, presents another major opportunity within the market’s evolving landscape.
Furthermore, the U.S. biomarker-based immunoassays market extends beyond healthcare delivery into research and academic institutions, where immunoassays are vital for biomarker discovery and validation. These institutions play a key role in driving innovation and forming partnerships with industry leaders, creating a cycle that supports new product development and clinical translation. Overall, the scope of the U.S. market is broad and dynamic, covering routine diagnostics, therapeutic monitoring, drug development, and academic research. This positions biomarker-based immunoassays as a fundamental technology within the evolving landscape of precision healthcare.
The demand for minimally invasive solutions has increased as clinicians look for reliable tools to detect diseases earlier and guide treatment decisions more accurately. This trend has led leading companies to focus on innovations in plasma and serum biomarkers, especially in fields such as oncology and neurology, where early diagnosis can greatly improve patient outcomes. In this context, several product innovations highlight the growing significance of blood-based biomarker immunoassays in clinical practice. For example, in April 2024 Roche's Elecsys pTau217 plasma biomarker test, developed with Eli Lilly, received Breakthrough Device Designation from the U.S. FDA, showing its potential to transform Alzheimer’s diagnosis. This test helps healthcare providers identify amyloid pathology, a key aspect of Alzheimer's disease, which can enable earlier, more accurate diagnoses. By improving access to timely diagnosis, the test not only improves patient care but also encourages patient participation in clinical trials and access to disease-modifying treatments, further increasing the demand for innovative blood-based biomarker tests in the U.S.
This product will be delivered within 1-3 business days.
Alongside therapeutic uses, the market is expanding due to technological progress and digital integration. Automated immunoassay platforms combined with artificial intelligence for data analysis are supporting high-throughput and very sensitive biomarker testing. This growth is not limited to central labs but also reaches decentralized healthcare models, like point-of-care and at-home testing options. The use of saliva-based biomarker immunoassays, which are less invasive and simpler to collect, presents another major opportunity within the market’s evolving landscape.
Furthermore, the U.S. biomarker-based immunoassays market extends beyond healthcare delivery into research and academic institutions, where immunoassays are vital for biomarker discovery and validation. These institutions play a key role in driving innovation and forming partnerships with industry leaders, creating a cycle that supports new product development and clinical translation. Overall, the scope of the U.S. market is broad and dynamic, covering routine diagnostics, therapeutic monitoring, drug development, and academic research. This positions biomarker-based immunoassays as a fundamental technology within the evolving landscape of precision healthcare.
The demand for minimally invasive solutions has increased as clinicians look for reliable tools to detect diseases earlier and guide treatment decisions more accurately. This trend has led leading companies to focus on innovations in plasma and serum biomarkers, especially in fields such as oncology and neurology, where early diagnosis can greatly improve patient outcomes. In this context, several product innovations highlight the growing significance of blood-based biomarker immunoassays in clinical practice. For example, in April 2024 Roche's Elecsys pTau217 plasma biomarker test, developed with Eli Lilly, received Breakthrough Device Designation from the U.S. FDA, showing its potential to transform Alzheimer’s diagnosis. This test helps healthcare providers identify amyloid pathology, a key aspect of Alzheimer's disease, which can enable earlier, more accurate diagnoses. By improving access to timely diagnosis, the test not only improves patient care but also encourages patient participation in clinical trials and access to disease-modifying treatments, further increasing the demand for innovative blood-based biomarker tests in the U.S.
U.S. Biomarker-Based Immunoassays Market Report Segmentation
This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. The analyst has segmented the U.S biomarker-based immunoassays market on the basis sample, product, biomarkers, diseases, end use and region.Sample Outlook (Revenue, USD Million, 2021-2033)
- Blood
- Tissue
- Urine
- Saliva
Product Outlook (Revenue, USD Million, 2021-2033)
- Consumables
- Instruments/Analyzers
- Reagent & Kits
- Services
Biomarker Outlook (Revenue, USD Million, 2021-2033)
- Safety & toxicity biomarkers
- Efficacy & Pharmacodynamic Biomarkers
- Predictive & Prognostic Biomarkers
- Surrogate/Exploratory Biomarkers
Diseases Outlook (Revenue, USD Million, 2021-2033)
- Cancer
- Cardiovascular Diseases
- Neurological Diseases
- Immunological Diseases
- Others
End Use Outlook (Revenue, USD Million, 2021-2033)
- Hospitals & Clinics
- Diagnostic Laboratories
- Research & Academic Institutes
- Others
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the industry across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segmental and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. U.S. Biomarker-Based Immunoassays Market Variables, Trends & Scope
Chapter 4. U.S. Biomarker-Based Immunoassays Market: Sample Estimates & Trend Analysis
Chapter 5. U.S. Biomarker-Based Immunoassays Market: Product Estimates & Trend Analysis
Chapter 6. U.S. Biomarker-Based Immunoassays Market: Biomarker Estimates & Trend Analysis
Chapter 7. U.S. Biomarker-Based Immunoassays Market: Diseases Estimates & Trend Analysis
Chapter 8. U.S. Biomarker-Based Immunoassays Market: End-use Estimates & Trend Analysis
Chapter 9. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The major companies profiled in this U.S. Biomarker-based Immunoassays market report include:- F. Hoffmann-La Roche AG
- Abbott
- Thermo Fisher Scientific Inc
- Erofins Scientific
- QIAGEN
- Bio-Rad Laboratories, Inc.
- Siemens Healthineers AG
- Merck KGaA
- PerkinElmer Inc.
- Agilent Technologies, Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | August 2025 |
| Forecast Period | 2024 - 2033 |
| Estimated Market Value ( USD | $ 2.17 Billion |
| Forecasted Market Value ( USD | $ 3.68 Billion |
| Compound Annual Growth Rate | 5.9% |
| Regions Covered | United States |
| No. of Companies Mentioned | 11 |
